Fortress Biotech to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 Dec 14, 2017
Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial Dec 11, 2017
Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting Dec 11, 2017
Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis Dec 11, 2017
Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Diseases With Unmet Medical Needs Dec 05, 2017
Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel Deaconess Medical Center, to Develop CRISPR/Cas9-Enhanced CAR T Therapies Dec 04, 2017
Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller Nov 14, 2017
Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights Nov 14, 2017
Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights Nov 09, 2017
Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights Nov 09, 2017
